Challenges in managing disorders of sex development associated with adrenal dysfunction

References

• Grinspon RP, Bergadá I, Rey RA. Male hypogonadism and disorders of sex development. Front Endocrinol. 2020;11:211. doi: 10.3389/fendo.2020.00211
   PubMed Web of Science ®Google Scholar
• Josso N, Rey RA. What does AMH tell us in pediatric disorders of sex development? Front Endocrinol. 2020;11:619. doi: 10.3389/fendo.2020.00619
   PubMed Web of Science ®Google Scholar
• Rey RA, Grinspon RP. Normal male sexual differentiation and aetiology of disorders of sex development. Best Pract Res Clin Endocrinol Metab. 2011;25(2):221–238. doi: 10.1016/j.beem.2010.08.013
   PubMed Web of Science ®Google Scholar
• Merke DP, Auchus RJ, Ingelfinger JR. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med. 2020;383(13):1248–1261. doi: 10.1056/NEJMra1909786
   PubMed Web of Science ®Google Scholar
• Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, et al. Congenital adrenal hyperplasia-Current insights in pathophysiology, diagnostics, and management. Endocr Rev. 2022;43(1):91–159. doi: 10.1210/endrev/bnab016
   PubMed Web of Science ®Google Scholar
• Martinerie L, Munier M, Le Menuet D, et al. The mineralocorticoid signaling pathway throughout development: expression, regulation and pathophysiological implications. Biochimie. 2013;95(2):148–157. doi: 10.1016/j.biochi.2012.09.030
   PubMed Web of Science ®Google Scholar
• El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet. 2017;390(10108):2194–2210. doi: 10.1016/S0140-6736(17)31431-9
   PubMed Web of Science ®Google Scholar
• Honour JW, Anderson JM, Shackleton CH. Difficulties in the diagnosis of congenital adrenal hyperplasia in early infancy: the 11 beta-hydroxylase defect. Acta Endocrinol (Copenh). 1983;103(1):101–109. doi: 10.1530/acta.0.1030101
   PubMedGoogle Scholar
• Bulsari K, Falhammar H. Clinical perspectives in congenital adrenal hyperplasia due to 11beta-hydroxylase deficiency. Endocrine. 2017;55(1):19–36. doi: 10.1007/s12020-016-1189-x
   PubMed Web of Science ®Google Scholar
• Khattab A, Haider S, Kumar A, et al. Clinical, genetic, and structural basis of congenital adrenal hyperplasia due to 11beta-hydroxylase deficiency. Proc Natl Acad Sci U S A. 2017;114(10):E1933–E40. doi: 10.1073/pnas.1621082114
   PubMed Web of Science ®Google Scholar
• Flück CE, Tajima T, Pandey AV, et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet. 2004;36(3):228–230. doi: 10.1038/ng1300
   PubMed Web of Science ®Google Scholar
• Krone N, Reisch N, Idkowiak J, et al. Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. J Clin Endocrinol Metab. 2012;97(2):E257–67. doi: 10.1210/jc.2011-0640
   PubMed Web of Science ®Google Scholar
• Arlt W, Walker EA, Draper N, et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet. 2004;363(9427):2128–2135. doi: 10.1016/S0140-6736(04)16503-3
   PubMed Web of Science ®Google Scholar
• Miller WL. MECHANISMS in ENDOCRINOLOGY: rare defects in adrenal steroidogenesis. Eur J Endocrinol. 2018; 179(3):R125–R41. doi: 10.1530/EJE-18-0279
   PubMed Web of Science ®Google Scholar
• Güran T, Kara C, Yildiz M, et al. Revisiting classical 3beta-hydroxysteroid dehydrogenase 2 deficiency: lessons from 31 pediatric cases. J Clin Endocrinol Metab. 2020;105(3):dgaa022. doi: 10.1210/clinem/dgaa022
   PubMedGoogle Scholar
• Finkielstain GP, Vieites A, Bergadá I, et al. Disorders of sex development of adrenal origin. Front Endocrinol. 2021;12:770782. doi: 10.3389/fendo.2021.770782
   PubMed Web of Science ®Google Scholar
• Al Alawi AM, Nordenstrom A, Falhammar H. Clinical perspectives in congenital adrenal hyperplasia due to 3beta-hydroxysteroid dehydrogenase type 2 deficiency. Endocrine. 2019;63(3):407–421. doi: 10.1007/s12020-018-01835-3
   PubMed Web of Science ®Google Scholar
• Grinspon RP, Castro S, Rey RA. Up-to-date clinical and biochemical workup of the child and the adolescent with a suspected disorder of sex development. Horm Res Paediatr. 2023; 96(2):116–127. doi: 10.1159/000519895
   PubMed Web of Science ®Google Scholar
• Bose HS, Sugawara T, Strauss JF, et al. The pathophysiology and genetics of congenital Lipoid Adrenal Hyperplasia. N Engl J Med. 1996;335(25):1870–1879. doi: 10.1056/NEJM199612193352503
   PubMed Web of Science ®Google Scholar
• Kolli V, Kim H, Torky A, et al. Characterization of the CYP11A1 nonsynonymous variant p.E314K in children presenting with adrenal insufficiency. J Clin Endocrinol Metab. 2019;104(2):269–276. doi: 10.1210/jc.2018-01661
   PubMed Web of Science ®Google Scholar
• Miller WL. Disorders in the initial steps of steroid hormone synthesis. J Steroid Biochem Mol Biol. 2017;165(Pt A):18–37. doi: 10.1016/j.jsbmb.2016.03.009
   PubMedGoogle Scholar
• Kurnaz E, Kartal Baykan E, Turkyilmaz A, et al. Genotypic sex and severity of the disease determine the time of Clinical presentation in steroid 17alpha-Hydroxylase/17,20-lyase deficiency. Horm Res Paediatr. 2020;93(9–10):558–566. doi: 10.1159/000515079
   PubMed Web of Science ®Google Scholar
• Lopez Dacal J, Prada S, Correa Brito L, et al. Testicular dysfunction at diagnosis in children and teenagers with haematopoietic malignancies improves after initial chemotherapy. Front Endocrinol. 2023;14. doi: 10.3389/fendo.2023.1135467
   PubMed Web of Science ®Google Scholar
• Auchus RJ. Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic. J Steroid Biochem Mol Biol. 2017;165:71–78. doi: 10.1016/j.jsbmb.2016.02.002
   PubMed Web of Science ®Google Scholar
• Mallappa A, Merke DP. Management challenges and therapeutic advances in congenital adrenal hyperplasia. Nat Rev Endocrinol. 2022;18(6):337–352. doi: 10.1038/s41574-022-00655-w
   PubMed Web of Science ®Google Scholar
• Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine society Clinical Practice guideline. J Clin Endocrinol Metab. 2018;103(11):4043–4088. doi: 10.1210/jc.2018-01865
   PubMed Web of Science ®Google Scholar
• Auer MK, Nordenstrom A, Lajic S, et al. Congenital adrenal hyperplasia. Lancet. 2023;401(10372):227–244. doi: 10.1016/S0140-6736(22)01330-7
   PubMed Web of Science ®Google Scholar
• Porter J, Withe M, Ross RJ. Immediate-release granule formulation of hydrocortisone, Alkindi(R), for treatment of paediatric adrenal insufficiency (infacort development programme). Expert Rev Endocrinol Metab. 2018;13(3):119–124. doi: 10.1080/17446651.2018.1455496
   PubMed Web of Science ®Google Scholar
• Rowlands A, Deeb A, Ladjouze A, et al. Access to fludrocortisone and to hydrocortisone in children with congenital adrenal hyperplasia in the WHO Eastern Mediterranean Region: it takes a village…. BMJ Glob Health. 2021;6(10):e007195. doi: 10.1136/bmjgh-2021-007195
   PubMed Web of Science ®Google Scholar
• Charmandari E, Hindmarsh PC, Johnston A, et al. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. J Clin Endocrinol Metab. 2001;86(6):2701–2708. doi: 10.1210/jcem.86.6.7522
   PubMed Web of Science ®Google Scholar
• Bonfig W. Growth and development in children with classic congenital adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):39–42. doi: 10.1097/MED.0000000000000308
   PubMedGoogle Scholar
• Nimkarn S, Lin-Su K, Berglind N, et al. Aldosterone-to-renin ratio as a marker for disease severity in 21-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2007;92(1):137–142. doi: 10.1210/jc.2006-0964
   PubMed Web of Science ®Google Scholar
• Hahner S, Spinnler C, Fassnacht M, et al. High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J Clin Endocrinol Metab. 2015;100(2):407–416. doi: 10.1210/jc.2014-3191
   PubMed Web of Science ®Google Scholar
• Allolio B. Extensive expertise in endocrinology. Adrenal crisis. Eur J Endocrinol. 2015;172(3):R115–24. doi: 10.1530/EJE-14-0824
   PubMed Web of Science ®Google Scholar
• Nordenstrom A, Falhammar H, Lajic S. Current and novel treatment strategies in children with congenital adrenal hyperplasia. Horm Res Paediatr. 2022 Jan 27. doi:10.1159/000522260. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• El-Maouche D, Hargreaves CJ, Sinaii N, et al. Longitudinal assessment of Illnesses, stress dosing, and illness sequelae in patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2018;103(6):2336–2345. doi: 10.1210/jc.2018-00208
   PubMed Web of Science ®Google Scholar
• Rey RA. Recent advancement in the treatment of boys and adolescents with hypogonadism. Ther Adv Endocrinol Metab. 2022;13:20420188211065660. doi: 10.1177/20420188211065660
   Web of Science ®Google Scholar
• Dunkel L, Quinton R. Induction of puberty. Eur J Endocrinol. 2014;170(6):R229–R39. doi: 10.1530/EJE-13-0894
   PubMed Web of Science ®Google Scholar
• Prete A, Auchus RJ, Ross RJ. Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. 2021;186(1):R1–R14. doi: 10.1530/EJE-21-0794
   PubMed Web of Science ®Google Scholar
• Debono M, Mallappa A, Gounden V, et al. Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers. Eur J Endocrinol. 2015;173(6):727–737. doi: 10.1530/EJE-15-0064
   PubMed Web of Science ®Google Scholar
• Jha S, Turcu AF, Sinaii N, et al. 11-oxygenated androgens useful in the setting of discrepant conventional biomarkers in 21-hydroxylase deficiency. J Endocr Soc. 2021;5(2):bvaa192. doi: 10.1210/jendso/bvaa192
   PubMed Web of Science ®Google Scholar
• Claahsen-van der Grinten HL, Stikkelbroeck N, Falhammar H, et al. MANAGEMENT of ENDOCRINE DISEASE: gonadal dysfunction in congenital adrenal hyperplasia. Eur J Endocrinol. 2021;184(3):R85–R97. doi: 10.1530/EJE-20-1093
   PubMedGoogle Scholar
• Roche EF, Charmandari E, Dattani MT, et al. Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report. Clin Endocrinol (Oxf). 2003;58(5):589–596. doi: 10.1046/j.1365-2265.2003.01757.x
   PubMed Web of Science ®Google Scholar
• Finkielstain GP, Kim MS, Sinaii N, et al. Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2012;97(12):4429–4438. doi: 10.1210/jc.2012-2102
   PubMed Web of Science ®Google Scholar
• Falhammar H, Frisen L, Hirschberg AL, et al. Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase deficiency: a Swedish population-based national cohort study. J Clin Endocrinol Metab. 2015;100(9):3520–3528. doi: 10.1210/JC.2015-2093
   PubMed Web of Science ®Google Scholar
• Turcu AF, Mallappa A, Elman MS, et al. 11-oxygenated androgens are biomarkers of adrenal volume and testicular adrenal rest tumors in 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2017;102(8):2701–2710. doi: 10.1210/jc.2016-3989
   PubMed Web of Science ®Google Scholar
• Idkowiak J, O’Riordan S, Reisch N, et al. Pubertal presentation in seven patients with congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. J Clin Endocrinol Metab. 2011;96(3):E453–62. doi: 10.1210/jc.2010-1607
   PubMed Web of Science ®Google Scholar
• Casteràs A, De SP, Rumsby G, et al. Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate. Clin Endocrinol (Oxf). 2009;70(6):833–837. doi: 10.1111/j.1365-2265.2009.03563.x
   PubMed Web of Science ®Google Scholar
• Martínez-Aguayo A, Rocha A, Rojas N, et al. Testicular adrenal rest tumors and Leydig and Sertoli cell function in boys with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2007;92(12):4583–4589. doi: 10.1210/jc.2007-0383
   PubMed Web of Science ®Google Scholar
• Mooij CF, Webb EA, Claahsen van der Grinten HL, et al. Cardiovascular health, growth and gonadal function in children and adolescents with congenital adrenal hyperplasia. Arch Dis Child. 2017;102(6):578–584. doi: 10.1136/archdischild-2016-311910
   PubMed Web of Science ®Google Scholar
• Muthusamy K, Elamin MB, Smushkin G, et al. Clinical review: adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2010;95(9):4161–4172. doi: 10.1210/jc.2009-2616
   PubMed Web of Science ®Google Scholar
• Tamhane S, Rodriguez-Gutierrez R, Iqbal AM, et al. Cardiovascular and metabolic outcomes in congenital adrenal hyperplasia: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2018;103(11):4097–4103. doi: 10.1210/jc.2018-01862
   PubMed Web of Science ®Google Scholar
• Torky A, Sinaii N, Jha S, et al. Cardiovascular disease risk factors and metabolic morbidity in a longitudinal study of congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2021;106(12):e5247–e57. doi: 10.1210/clinem/dgab133
   PubMed Web of Science ®Google Scholar
• Volkl TM, Simm D, Dotsch J, et al. Altered 24-hour blood pressure profiles in children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2006;91(12):4888–4895. doi: 10.1210/jc.2006-1069
   PubMed Web of Science ®Google Scholar
• Sarafoglou K, Merke DP, Reisch N, et al. Interpretation of steroid biomarkers in 21-hydroxylase deficiency and their use in disease management. J Clin Endocrinol Metab. 2023;108(9):2154–2175. doi: 10.1210/clinem/dgad134
   PubMedGoogle Scholar
• Lawrence N, Bacila I, Dawson J, et al. Analysis of therapy monitoring in the international congenital adrenal hyperplasia registry. Clin Endocrinol (Oxf). 2022;97(5):551–561. doi: 10.1111/cen.14796
   PubMed Web of Science ®Google Scholar
• Miller WL. Congenital Adrenal Hyperplasia: time to Replace 17OHP with 21-deoxycortisol. Horm Res Paediatr. 2019;91(6):416–420. doi: 10.1159/000501396
   PubMed Web of Science ®Google Scholar
• Turcu AF, Nanba AT, Chomic R, et al. Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency. Eur J Endocrinol. 2016;174(5):601–609. doi: 10.1530/EJE-15-1181
   PubMed Web of Science ®Google Scholar
• Neumann U, Braune K, Whitaker MJ, et al. A prospective study of children aged 0-8 years with CAH and adrenal insufficiency treated with hydrocortisone granules. J Clin Endocrinol Metab. 2021;106(3):e1433–e40. doi: 10.1210/clinem/dgaa626
   PubMed Web of Science ®Google Scholar
• Merke DP, Mallappa A, Arlt W, et al. Modified-release hydrocortisone in congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2021;106(5):e2063–e77. doi: 10.1210/clinem/dgab051
   PubMed Web of Science ®Google Scholar
• Turcu AF, Mallappa A, Nella AA, et al. 24-hour profiles of 11-oxygenated C19 steroids and Δ5-steroid sulfates during oral and continuous subcutaneous glucocorticoids in 21-hydroxylase deficiency. Front Endocrinol. 2021;12. doi: 10.3389/fendo.2021.751191
   Web of Science ®Google Scholar
• El-Maouche D, Merke DP, Vogiatzi MG, et al. A phase 2, multicenter study of Nevanimibe for the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2020;105(8):2771–2778. doi: 10.1210/clinem/dgaa381
   PubMed Web of Science ®Google Scholar
• Auchus RJ, Buschur EO, Chang AY, et al. Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2014;99(8):2763–2770. doi: 10.1210/jc.2014-1258
   PubMed Web of Science ®Google Scholar
• Auchus RJ, Sarafoglou K, Fechner PY, et al. Crinecerfont lowers elevated hormone markers in adults with 21-hydroxylase deficiency congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2022;107(3):801–812. doi: 10.1210/clinem/dgab749
   PubMed Web of Science ®Google Scholar
• Sarafoglou K, Barnes CN, Huang M, et al. Tildacerfont in adults with classic congenital adrenal hyperplasia: results from two phase 2 studies. J Clin Endocrinol Metab. 2021;106(11):e4666–e79. doi: 10.1210/clinem/dgab438
   PubMed Web of Science ®Google Scholar
• A Ph2b to evaluate Tildacerfont in the reduction of glucocorticoid steroid doses in adult CAH. [cited 2023 Aug 16]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04544410
   Google Scholar
• A Ph2b to evaluate Clinical efficacy and safety of Tildacerfont in adult CAH. [cited 2023 16 Aug]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04457336
   Google Scholar
• Schroder MAM, Claahsen-van der Grinten HL. Novel treatments for congenital adrenal hyperplasia. Rev Endocr Metab Disord. 2022;23(3):631–645. doi: 10.1007/s11154-022-09717-w
   PubMed Web of Science ®Google Scholar
• Ruiz-Babot G, Balyura M, Hadjidemetriou I, et al. Modeling congenital adrenal hyperplasia and testing interventions for adrenal insufficiency using donor-specific reprogrammed cells. Cell Rep. 2018;22(5):1236–1249. doi: 10.1016/j.celrep.2018.01.003
   PubMed Web of Science ®Google Scholar
• Naiki Y, Miyado M, Horikawa R, et al. Extra-adrenal induction of Cyp21a1 ameliorates systemic steroid metabolism in a mouse model of congenital adrenal hyperplasia. Endocr J. 2016;63(10):897–904. doi: 10.1507/endocrj.EJ16-0112
   PubMed Web of Science ®Google Scholar
• Bornstein SR, Malyukov M, Heller C, et al. New horizons: novel adrenal regenerative therapies. J Clin Endocrinol Metab. 2020;105(9):3103–3107. doi: 10.1210/clinem/dgaa438
   PubMed Web of Science ®Google Scholar